Procter & Gamble Health Limited has announced the successful sale of immovable properties in Mumbai, generating a substantial profit for the healthcare company. The transaction was completed on April 30, 2026, marking a significant asset disposal for the organization.

Transaction Details

The company executed an indenture of sale for the disposal of certain immovable properties situated in Mumbai on April 30, 2026. This strategic move is expected to contribute positively to the company's financial performance.

Regulatory Compliance

Procter & Gamble Health Limited has fulfilled its regulatory obligations by informing both major stock exchanges about this material transaction. The company submitted the required intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to:

• BSE Limited (Scrip Code: 500126)
• National Stock Exchange of India Limited (Scrip Code: PGHL)

Financial Impact

The property sale is projected to generate approximately ₹32 crores in profit for Procter & Gamble Health Limited. This significant gain from the disposal of real estate assets demonstrates the company's ability to optimize its asset portfolio and generate value from non-core holdings.

Corporate Authorization

The regulatory filing was digitally signed by Zeal Rupani, Company Secretary of Procter & Gamble Health Limited, on April 30, 2026, at 22:41:29 +05'30'. The formal communication ensures transparency and compliance with stock exchange requirements for material events that could impact investor decisions.

Procter & Gamble Health Limited has formally notified stock exchanges that it does not qualify as a 'Large Corporate' under the Securities and Exchange Board of India's framework for fund raising by large entities. The disclosure was made to both BSE and NSE on April 6, 2026, through Company Secretary Zeal Rupani.

Regulatory Compliance Framework

The company's disclosure relates to SEBI Circular No SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, along with subsequent amendments, including the latest circular no. SEBI/HO/DDHS/P/CIR/2021/613 dated April 13, 2022. These circulars establish requirements for disclosure of fund raising by issuance of debt securities by large entities.

Company Financial Position

Procter & Gamble Health Limited provided specific details regarding its financial status in the mandatory disclosure format:

SEBI Framework Implications

Under the SEBI framework, entities classified as Large Corporates are subject to specific borrowing requirements through debt securities. The regulations include provisions for fines in case of shortfall in mandatory borrowing through debt markets. Beginning from FY2022, a fine of 0.20% of the shortfall is levied by stock exchanges at the end of the two-year block period.

Corporate Governance

The disclosure was signed digitally by Company Secretary Zeal Rupani on April 6, 2026, at 10:33:45 +05'30'. The company has requested both BSE and NSE to acknowledge receipt of this compliance disclosure, demonstrating adherence to regulatory transparency requirements.